About JITC

Recent ArticlesJITC Editorial Board Highly Accessed ArticlesJITC DigestJITC Reading List Follow JITC on X

Reviewer_2.png
The quality of the journal could not be sustained without the efforts of our dedicated reviewers.

Become a Reviewer

For_Authors.png
Help enrich communication and advance scientific understanding in cancer immunotherapy.

For Authors

Editor.png
JITC's distinguished Editorial Board highlights featured content from the journal and beyond.

From the Editors

Collections.png
Readers have the opportunity to view JITC's special editions and theme-focused collections.

JITC Collections




Get to Know JITC's Leadership

JITC is pleased to welcome Michael T. Lotze, MD as the journal's new Editor-in-Chief. He is working with Interim Editor-in-Chief, James L. Gulley, MD, PhD, FACP, throughout 2024 as leadership is transferred. In addition, Sjoerd H. van der Burg, PhD has been promoted to Deputy Editor-in-Chief after a tremendous year of support in an interim capacity in 2023. Read more about this phenomenal group of leaders. 

Get the chance to meet these editors at conferences throughout the year. From Barcelona, Spain to San Diego, CA, our editors will be available to meet with you and learn about your research. Check back for more information on Meet-the-Editor opportunities in 2024. 




JITC Awards

Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.

Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.

The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.

JITC at SITC 2024

There will be number of JITC-related events at the upcoming SITC Annual Meeting and Pre-Conference Programs, November 6th–10th. 
 

Friday, November 8th 

  • A remembrance of Dr. Jeffrey Weber, a former JITC editor, author, reviewer, and beloved member of the I-O community, will be held prior to the awards ceremony. (7:50–7:55 a.m. CT – Hall A3 – Session 101)
  • JITC Managing Editor Andrea Kunz is the recipient of this year’s Pedro J. Romero Service to JITC Award and will be recognized during the award ceremony. (7:55–8:20 a.m. CT – Hall A3 – Session 101)

Saturday, November 9th 

  • Editor-in-Chief Dr. Michael Lotze will host a Meet-the-Editor session 12:30–1:30 p.m. CT at the SITC booth (#401).
  • This year’s JITC Best Paper Award recipients and the journal’s Peer Review Mentorship Program class of 2024 will receive recognition during the awards ceremony. (6:40–7:10 p.m. CT – Hall A3 – Session 209)



APC Discounts

As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 35 percent discount on Article Processing Charges (APCs) for all accepted JITC articles submitted in 2024. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author. 

JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. 

For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.



Highly Accessed Articles

What is the article Altmetric Attention Score?


Altmetric_Score_donut.pngIndicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response

Article has an altmetric score of 385
Saraí G De León-Rodríguez, Cristina Aguilar-Flores, Julián A Gajón, Ángel Juárez-Flores, Alejandra Mantilla, Raquel Gerson-Cwilich, José Fabián Martínez-Herrera, Diana Alejandra Villegas-Osorno, Claudia T Gutiérrez-Quiroz, Sergio Buenaventura-Cisneros, Mario Alberto Sánchez-Prieto, Edmundo Castelán-Maldonado, Samuel Rivera Rivera, Ezequiel M Fuentes-Pananá and Laura C Bonifaz


 

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy

Article has an altmetric score of 385
Haider Al-janabi, Katy Moyes, Richard Allen, Matthew Fisher, Mateus Crespo, Bora Gurel, Pasquale Rescigno, Johann de Bono, Harry Nunns, Christopher Bailey, Anna Junker-Jensen, Munitta Muthana, Wayne A Phillips, Helen B Pearson, Mary-Ellen Taplin, Janet E Brown and Claire E Lewis


 

POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma

Hao Wang, Yuan Liang, Zheng Liu, Rui Zhang, Jiashuo Chao, Mingming Wang, Mu Liu, Lei Qiao, Zhengfeng Xuan, Haitao Zhao and Ling Lu


 

Browse the Current Issue

Read More